Opiate tolerance and dependence: Receptors, G-proteins, and antiopiates

Peptides

Volumn 19, Issue 9, 1998, Pages 1603-1630

  Harrison, Laura M ^a,b   Kastin, Abba J ^a   Zadina, James E ^a,c  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiopiates; Dependence; G proteins; Opiate receptors; Opioid peptides; Tolerance

Indexed keywords

DELTA OPIATE RECEPTOR; ENDORPHIN DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NEUROPEPTIDE FF; NOCICEPTIN; OPIATE DERIVATIVE; OPIATE RECEPTOR; PRODYNORPHIN; PROENKEPHALIN; PROOPIOMELANOCORTIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TYROSYLPROLYLLEUCYLGLYCINAMIDE;

DRUG DEPENDENCE; DRUG TOLERANCE; HUMAN; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW;

DRUG TOLERANCE; GTP-BINDING PROTEINS; NARCOTICS; OPIOID-RELATED DISORDERS; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION;

EID: 0032428284     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(98)00126-0     Document Type: Review

References (253)

1. Akil, H.; Watson, S. J. Cloning of kappa opioid receptors: functional significance and future directions. Prog. Brain Res. 100:81-86; 1994.
2. Allard M.; Zajac J.-M.; Simonnet G. Autoradiographic distribution of receptors to FLFQPQPRFamide, a morphine-modulating peptide, in rat central nervous system. Neuroscience 49:101-116; 1992.
3. Allard M.; Geoffre S.; Legendre P.; Vincent J. D.; Simonnet G. Characterization of rat spinal cord receptors to FLFQPQRFamide, a mammalian morphine modulating peptide: a binding study. Brain Res. 500:169-176; 1989.
4. Altier N.; Stewart J. Neuropeptide FF in the VTA blocks the analgesic effects of both intra-VTA morphine and exposure to stress. Brain Res. 758:250-254; 1997.
5. Arden J. R.; Segredo V.; Wang Z.; Lameh J.; Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J. Neurochem. 65:1636-1645; 1995.
6. Arvidsson U.; Dado R. J.; Riedl M.; Lee J.-H.; Law P.-Y.; Loh H. H.; Elde R.; Wessendorf M. W. δ-opioid receptor immunoreactivity: distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin. J. Neurosci. 15:1215-1235; 1995.
7. Arvidsson U.; Riedl M.; Chakrabarti S.; Lee J.-H.; Nakano A. H.; Dado R. J.; Loh H. H.; Law P.-Y.; Wessendorf M. W.; Elde R. Distribution and targeting of a μ-opioid receptor (MOR1) in brain and spinal cord. J. Neurosci. 15:3328-3341; 1995.
8. Arvidsson U.; Riedl M.; Chakrabarti S.; Vulchanova L.; Lee J.-H.; Nakano A. H.; Lin Q.; Loh H. H.; Law P.-Y.; Wessendorf M. W.; Elde, R. The κ-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids. Proc. Natl. Acad. Sci. USA 92:5062-5066; 1995.
9. Attali B.; Gouarderes C.; Mazarguil H.; Audigier Y.; Cros J. Evidence for multiple "kappa" binding sites by use of opioid peptides in the guinea-pig lumbro-sacral spinal cord. Neuropeptides 3:53-64; 1982.
10. 3H]-etorphine binding in guinea-pig striatum after blockade of mu and delta sites. Life Sci. 31:1287-1290; 1982.
11. Avidor-Reiss T.; Zippel R.; Levy R.; Saya D.; Ezra V.; Barg J.; Matus-Leibovitch N.; Vogel Z. κ-opioid receptor-transfected cell lines: modulation of adenylyl cyclase activity following acute and chronic morphine treatments. FEBS Lett. 361:70-74; 1995.
12. Barchfeld C. C.; Medzihradsky F. Receptor-mediated stimulation of brain GTPase by opiates in normal and dependent rats. Biochem. Biophys. Res. Commun. 121:641-648; 1984.
13. Bare L. A.; Mansson E.; Yang D. Expression of two variants of the human μ opioid receptor mRNA in SK-N-SH cells and human brain. FEBS Lett. 354:213-216; 1994.
14. Baumhaker Y.; Gafni M.; Keren O.; Sarne Y. Selective and interactive down-regulation of μ- and δ-opioid receptors in human neuroblastoma SK-N-SH cells. Mol. Pharmacol. 44: 461-467; 1993.
15. 35S]GTPγS binding: a tool to evaluate functional activity of a cloned opioid receptor transiently expressed in COS cells. Neurochem. Res. 21:1301-1307; 1996.
16. Belcheva M.; Barg J.; McHale R. J.; Dawn S.; Ho M. T.; Ignatova E.; Coscia C. J. Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine. Mol. Pharmacol. 44:173-179; 1993.
17. Bhargava H.; Gulati A. Down-regulation of brain and spinal cord μ-opiate receptors in morphine tolerant-dependent rats. Eur. J. Pharmacol. 190:305-311; 1990.
18. Bhoola K. D.; Pay S. Opioid inhibition of adenylate cyclase in the striatum and vas deferens of the rat. Br. J. Pharmacol. 89:109-118; 1986.
19. Blake A. D.; Bot G.; Freeman J. C.; Reisine T. Differential opioid agonist regulation of the mouse μ opioid receptor. J. Biol. Chem. 272:782-790; 1997.
20. Blake A. D.; Bot G.; Li S.; Freeman J. C.; Reisine T. Differential agonist regulation of the human κ-opioid receptor. J. Neurochem. 68:1846-1852; 1997.
21. Blume A. J. Opiate binding to membrane preparations of neuroblastoma x glioma hybrid cells NG108-15: effects of ions and nucleotides. Life Sci. 22:1843-1852; 1978.
22. + and GTP. Proc. Natl. Acad. Sci. USA 76:5626-5630; 1979.
23. Bokoch G. M.; Katada T.; Northup J. K.; Ui M.; Gilman A. G. Purification and properties of the inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase. J. Biol. Chem. 259:3560-3567; 1984.
24. Brady L. S.; Herkenham M.; Long J. B.; Rothman R. B. Chronic morphine increases μ-opiate receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 477: 382-386; 1989.
25. Breivogel C. S.; Selley D. E.; Childers S. R. Acute and chronic effects of opioids on μ and δ receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes. J. Neurochem. 68:1462-1472; 1997.
26. Brodsky M.; Elliot K.; Hynansky A.; Inturrisi C. E. CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Res. Bull. 38: 135-141; 1995.
27. Buzas B.; Izenwasser S.; Portoghese P. S.; Cox B. M. Evidence for delta opioid receptor subtypes regulating adenylyl cyclase activity in rat brain. Life Sci. 54:101-106; 1994.
28. Buzas B.; Rosenberger J.; Cox B. M. Regulation of δ-opioid receptor mRNA levels by receptor-mediated and direct activation of the adenylyl cyclase-protein kinase A pathway. J. Neurochem. 68:610-615; 1997.
29. Bzdega T.; Chin H.; Kim H.; Jung H. H.; Kozek C. A.; Klee W. A. Regional expression and chromosomal localization of the δ opiate receptor gene. Proc. Natl. Acad. Sci. USA 90: 9305-9309; 1993.
30. Carter B. D.; Medzihradsky F. Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells. Mol. Pharmacol. 43:465-473; 1993.
31. o mediates the coupling of the μ opioid receptor to adenylyl cyclase in cloned neural cells and brain. Proc. Natl. Acad. Sci. USA 90:4062-4066; 1993.
32. Cassel D.; Selinger Z. Catecholamine-stimulated GTPase activity in turkey erythrocyte membranes. Biochim. Biophys. Acta 452:538-551; 1976.
33. Castelli M. P.; Melis M.; Mameli M.; Fadda P.; Diaz G.; Gessa G. L. Chronic morphine and naltrexone fail to modify μ-opioid receptor mRNA levels in the rat brain. Mol. Brain Res. 45:149-153; 1997.
34. 2A cells stably expressing a cloned μ-opioid receptor: a specific cellular model to study acute and chronic effects of morphine. Mol. Brain Res. 30:269-278; 1995.
35. 32P]GTP labeling of multiple G protein α subunits. J. Neurochem. 64:2534-2543; 1995.
36. Chakrabarti S.; Yang W.; Law P.-Y.; Loh H. H. The μ-opioid receptor down-regulates differently from the δ-opioid receptor: requirement for a high affinity receptor/G protein complex formation. Mol. Pharmacol. 52:105-113; 1997.
37. Chang K.-J.; Cuatrecasas P. Multiple opiate receptors: enkephalins and morphine bind to receptors of different specificity. J. Biol. Chem. 254:2610-2618; 1979.
38. Chang K.-J.; Eckel R. W.; Blanchard S. G. Opioid peptides induce reduction of enkephalin receptors in cultured neuroblastoma cells. Nature 296:446-448; 1982.
39. Chang K.-J.; Hazum E.; Cuatrecasas P. Novel opiate binding sites selective for benzomorphan drugs. Proc. Natl. Acad. Sci. USA 78:4141-4145; 1981.
40. Chavkin C.; Goldstein A. Demonstration of a specific dynorphin receptor in guinea pig ileum myenteric plexus. Nature 291:591-593; 1981.
41. Chen Y.; Mestek A.; Liu J.; Hurley J. A.; Yu L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol. Pharmacol. 44:8-12; 1993.
42. Chen Y.; Mestek A.; Yu L. Molecular cloning of a rat κ opioid receptor reveals sequence similarities to the μ and δ opioid receptors. Biochem. J. 295:625-628; 1993.
43. Childers S. R. Opioid receptor-coupled second messenger systems. Life Sci. 48:1991-2003; 1991.
44. Childers S. R.; Snyder S. H. Guanine nucleotides differentiate agonist and antagonist interactions with opiate receptors. Life Sci. 23:759-762; 1978.
45. Clapman D. E.; Neer E. J. New roles for G-protein βγ-dimers in transmembrane signalling. Nature 365:403-406; 1993.
46. 3 subtype. J. Pharmacol. Exp. Ther. 251:461-468; 1989.
47. Codina J.; Hildebrandt J. D.; Sekura R. D.; Birnbaumer M.; Bryan J.; Manclark C. R.; Iyengar R.; Birnbaumer L. Ns and Ni, the stimulatory and inhibitory regulatory components of adenylyl cyclase. Purification of the human erythrocyte proteins without the use of activating regulatory ligands. J. Biol. Chem. 259:5871-5886; 1984.
48. Collier H. O. J.; Francis D. L. Morphine abstinence is associated with increased brain cyclic AMP. Nature 255:159-162; 1975.
49. Comb M.; Seeburg P. H.; Adelman J.; Eiden L.; Herbert E. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature 295:663-666; 1982.
50. Cox B. M.; Goldstein A.; Li C. H. Opioid activity of a peptide, β-lipotropin-(61-91), derived from β-lipotropin. Proc. Natl. Acad. Sci USA 73:1821-1823; 1976.
51. Cox B. M.; Opheim K. E.; Teschemacher H.; Goldstein A. A peptide-like substance from pituitary that acts like morphine. 2. Purification. Life Sci. 16:1777-1782; 1975.
52. Crain S. M.; Shen K.-F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. 11:77-81; 1990.
53. Crain S. M.; Shen K.-F. After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside. Brain Res. 575:13-24; 1992.
54. Crain S. M.; Shen K.-F. After GM1 ganglioside treatment of sensory neurons naloxone paradoxically prolongs the action potential but still antagonizes opioid inhibition. J. Pharmacol. Exp. Ther. 260:182-186; 1992.
55. Crain S. M.; Shen K.-F. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing potency and attenuating tolerance/dependence during chronic cotreatment. Proc. Natl. Acad. Sci. USA 92:10540-10544; 1995.
56. s-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Neurochem. Res. 21:1347-1351; 1996.
57. Cruciani R. A.; Dvorkin B.; Morris S. A.; Crain S. M.; Makman M. H. Direct coupling of opioid receptors to both stimulatory and inhibitory guanine nucleotide-binding proteins in F-11 neuroblastoma-sensory neuron hybrid cells. Proc. Natl. Acad. Sci. USA 90:3019-3023; 1993.
58. 353, located within the COOH-terminal of the δ opiate receptor, is involved in receptor down-regulation. J. Biol. Chem. 271:4073-4076; 1996.
59. 5]enkephalin binding sites by different mechanisms. Neuropharmacology 27:965-974; 1988.
60. Delfs J. M.; Kong H.; Mestek A.; Chen Y.; Yu L.; Reisine T.; Chesselet M.-F. Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level. J. Comp. Neurol. 345:46-68; 1994.
61. Devillers J.-P.; Boisserie F.; Laulin J.-P.; Larcher A.; Simonnet G. Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitory circuitry by stimulation of opioid receptors in rats. Brain Res. 700:173-181; 1995.
62. Devine D. P.; Reinscheid R. K.; Monsma F. J.; Civelli O.; Akil H. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res. 727:225-229; 1996.
63. Ding Y.-Q.; Kaneko T.; Nomura S.; Mizuno N. Immunohistochemical localization of μ-opioid receptors in the central nervous system of the rat. J. Comp. Anat. 367:375-402; 1996.
64. 6 glioma cell line expressing the μ opioid receptor. J. Pharmacol. Exp. Ther. 278:1121-1127; 1996.
65. 2 (Tyr-W-MIF-1). Peptides 13: 623-631; 1992.
66. Evans C. J.; Keith D. E.; Morrison H.; Magendzo K.; Edwards R. H. Cloning of a delta opioid receptor by functional expression. Science 258:1952-1955; 1992.
67. Fukada K.; Kato S.; Mori K.; Nishi M.; Takeshima H. Primary structures and expression from cDNAs of rat opioid receptor δ- and μ-subtypes. FEBS Lett. 327:311-314; 1993.
68. Galina Z. H.; Kastin A. J. Existence of antiopiate systems as illustrated by MIF-1/Tyr-MIF-1. Life Sci. 39:2153-2159; 1986.
69. George S. R.; Zastawny R. L.; Briones-Urbina R.; Cheng R.; Nguyen T.; Heiber M.; Kouvelas A.; Chan A. S.; O'Dowd, B. F. Distinct distributions of mu, delta and kappa opioid receptor mRNA in rat brain. Biochem. Biophys. Res. Commun. 205:1438-1444; 1994.
70. 2-adrenoceptors. Eur. J. Pharmacol. 298: 235-239; 1996.
71. 1-opioid receptor antagonist. Eur. J. Pharmacol. 316:33-38; 1996.
72. Gilbert P. E.; Martin W. R. The effects of morphine- and nalorphine-like drugs in the nondependent, morphine-dependent, and cyclazocine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 198:66-82; 1976.
73. Gilman A. G. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56:615-649; 1987.
74. Gintzler A. R.; Xu H. Different G proteins mediate the opioid inhibition or enhancement of evoked [5-methionine]enkephalin release. Proc. Natl. Acad. Sci. USA 88: 4741-4745; 1991.
75. Gistrak M. A.; Paul D.; Hahn E. F.; Pasternak G. W. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone. J. Pharmacol. Exp. Ther. 251:469-476; 1989.
76. Goldstein A.; Fischli W.; Lowney L. I.; Hunkapiller M.; Hood L. Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc. Natl. Acad. Sci. USA 78:7219-7223; 1981.
77. Goldstein A.; Lowney L. I.; Pal B. K. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc. Natl. Acad. Sci. USA 68:1742-1747; 1971.
78. Goldstein A.; Tachibana S.; Lowney L. I.; Hunkapiller M.; Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. USA 76:6666-6670; 1979.
79. Goodman C. B.; Emilien B.; Becketts K.; Cadet J. L.; Rothman R. B. Downregulation of mu-opioid binding sites following chronic administration of neuropeptide FF (NPFF) and morphine. Peptides 17:389-397; 1996.
80. Goodman R. R.; Pasternak G. W. Visualization of mu1 opiate receptors in rat brain by using a computerized autoradiographic subtraction technique. Proc. Natl. Acad. Sci. USA 82:6667-6671; 1985.
81. Gouarderes C.; Audigier Y.; Cros J. Benzomorphan binding sites in rat lumbro-sacral spinal cord. Eur. J. Pharmacol. 78:483-486; 1982.
82. Gouarderes C.; Jhamandas K.; Sutak M.; Zajac J.-M. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues. Br. J. Pharmacol. 117:493-501; 1996.
83. Gouarderes C.; Kar S.; Zajac J.-M. Presence of neuropeptide FF receptors in primary afferent fibres of the rat spinal cord. Neuroscience 74:21-27; 1996.
84. Greenberg M. J.; Painter S. D.; Doble K. E.; Nagle G. T.; Price D. A.; Lehman H. K. The molluscan neurosecretory peptide FMRFamide: comparative pharmacology and relationship to enkephalins. Fed. Proc. 42:82-86; 1983.
85. Gubler U.; Seeburg P.; Hoffman B. J.; Gage L. P.; Udenfriend S. Molecular cloning establishes proenkephalin as a precursor of enkephalin-containing peptides. Nature 295:206-208; 1982.
86. Hackler L.; Zadina J. E.; Ge L.-J.; Kastin A. J. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides 18:1635-1639; 1997.
87. Hao J.-X.; Wiesenfeld-Hallin Z.; Xu X.-J. Lack of cross-tolerance between the antinociceptive effect of intrathecal orphanin FQ and morphine in the rat. Neurosci. Lett. 223:49-52; 1997.
88. 35S]GTPyS binding in SH-SY5Y human neuroblastoma cells. Soc. Neurosci. Abst. 23:268; 1997.
89. Harrison L. M.; Kastin A. J.; Zadina J. E. Tyr-W-MIF-1 attenuates down-regulation of opiate receptors in SH-SY5Y human neuroblastoma cells. J. Pharmacol. Exp. Ther. 284: 611-617; 1998.
90. Harrison L. M.; Kastin A. J.; Zadina J. E. Differential effects of endomorphin-1, endomorphin-2, and Tyr-W-MIF-1 on activation of G-proteins in SH-SY5Y human neuroblastoma membranes. Peptides 19:749-753; 1998.
91. Heinricher M. M.; McGaraughty S.; Grandy D. K. Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla. J. Neurophysiol. 78:3351-3358; 1997.
92. Henderson G.; McKnight A. T. The orphan opioid receptor and its endogenous ligand - nociceptin/orphanin FQ. Trends Pharmacol. Sci. 18:293-300; 1997.
93. o, regulates neuronal calcium channels. Nature 325:445-447; 1987.
94. Hollt V.; Dum J.; Blasig J.; Schubert P.; Herz A. Comparison of in vivo and in vitro parameters of receptor binding in naive and tolerant/dependent rats. Life Sci. 16:1823-1828; 1975.
95. 2) in human brain cortex. Intl. J. Peptide Protein Res. 36:281-284; 1990.
96. 3H by synaptosomes. Life Sci. 10:201-213; 1971.
97. Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res. 88:295-308; 1975.
98. Hughes J.; Smith T.; Morgan B.; Fothergill L. Purification and properties of enkephalin - the possible endogenous ligand for the opiate receptor. Life Sci. 16:1753-1758; 1975.
99. Iyengar S.; Kim H. S.; Wood P. L. Effects of kappa opiate agonists on neurochemical and neuroendocrine indices: evidence for kappa receptor subtypes. Life Sci. 39:637-644; 1986.
100. Jenab S.; Kest B.; Inturrisi C. E. Assessment of delta opioid antinociception and receptor mRNA levels in mouse after chronic naltrexone treatment. Brain Res. 691: 69-75; 1995.
101. 6]enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 257: 1069-1075; 1991.
102. Kakadani H.; Furutani Y.; Takahashi H.; Noda M.; Morimoto Y.; Hirose T.; Asai M.; Inayama S.; Nakanishi S.; Numa S. Cloning and sequence analysis of cDNA for porcine β-neo-endorphin/dynorphin precursor. Nature 298:245-249; 1982.
103. Kazmi S. M. I.; Mishra R. K. Opioid receptors in human neuroblastoma SH-SY5Y cells: evidence for distinct morphine and enkephalin binding sites. Biochem. Biophys. Res. Commun. 137:813-820; 1986.
104. Kazmi S. M. I.; Mishra R. K. Comparative pharmacological properties and functional coupling of μ and δ opioid receptor sites in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 32:109-118; 1987.
105. Keith D. E.; Murray S. R.; Zaki P. A.; Chu P. C.; Lissin D. V.; Kang L.; Evans C. J.; von Zastrow M. Morphine activates opioid receptors without causing their rapid internalization. J. Biol. Chem. 271:19021-19024; 1996.
106. 2]deltorphin II tolerant mice. J. Neurosci. Res. 39:674-679; 1994.
107. Kieffer B. L.; Befort K.; Gaveriaux-Ruff C.; Hirth C. The δ-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characteristics. Proc. Natl. Acad. Sci. USA 89:12048-12052; 1992.
108. Kim D. S.; Chin H.; Klee W. A. Agonist regulation of the expression of the delta opioid receptor in NG108-15 cells. FEBS Lett. 376:11-14; 1995.
109. Kimura S.; Lewis R. V.; Stern A. S.; Rossier J.; Stein S.; Udenfriend S. Probable precursors of [Leu]enkephalin and [Met]enkephalin in adrenal medulla: peptides of 3-5 kilodaltons. Proc. Natl. Acad. Sci. USA 77:1681-1685; 1980.
110. Kivipelto L.; Majane E. A.; Yang H.-Y. T.; Panula P. Immunohistochemical distribution and partial characterization of FLFQPQRFamidelike peptides in the central nervous system. J. Comp. Anat. 286:269-287; 1989.
111. Klee W. A.; Streaty R. A. Narcotic receptor sites in morphine-dependent rats. Nature 248:61-63; 1974.
112. 2-adrenergic and μ-opioid spinal antinociception by neuropeptide FF. Peptides 16:973-977; 1995.
113. Koob G. F.; Bloom F. E. Cellular and molecular mechanisms of drug dependence. Science 242:715-723; 1988.
114. Koski G.; Klee W. A. Opiates inhibit adenylate cyclase by stimulating GTPase. Proc. Natl. Acad. Sci. USA 78:4185-4189; 1981.
115. Kosterlitz H. W.; Paterson S. J.; Robson L. E. Characterization of the κ-sub type of the opiate receptor in the guinea-pig brain. Br. J. Pharmacol. 73:939-949; 1981.
116. Kuhar M. J.; Pert C. B.; Snyder S. H. Regional distribution of opiate receptor binding in monkey and human brain. Nature 245:447-450; 1973.
117. Kurose H.; Katada T.; Amano T.; Ui M. Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via α-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells. J. Biol. Chem. 258:4870-4875; 1983.
118. Lake J. R.; Hammond M. V.; Shaddox R. C.; Hunsicker L. M.; Yang H. Y.-T.; Malin D. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. Neurosci. Lett. 132:29-32; 1991.
119. Laugwitz K.-L.; Offermanns S.; Spicher K.; Schultz G. μ and δ opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells. Neuron 10:233-242; 1993.
120. Law P. Y.; Hom D. S.; Loh H. H. Loss of receptor activity in neuroblastoma x glioma NG108-15 hybrid cells after chronic opiate treatment: a multiple step process. Mol. Pharmacol. 22:1-4; 1982.
121. Law P. Y.; Hom D. S.; Loh H. H. Opiate receptor down-regulation and desensitization in neuroblastoma x glioma NG108-15 hybrid cells are two separate cellular adaptation processes. Mol. Pharmacol. 24:413-424; 1983.
122. Law P. Y.; Wu J.; Koehler J. E.; Loh H. H. Demonstration and characterization of opiate inhibition of the striatal adenylate cyclase. J. Neurochem. 36:1834-1846; 1981.
123. Leventhal L.; Cole J. L.; Rossi G. C.; Pan X. X.; Pasternak G. W.; Bodnar R. J. Antisense oligodeoxynucleotides against the MOR-1 clone alter weight and ingestive responses in rats. Brain Res. 719:78-84; 1996.
124. Leventhal L.; Stevens L. B.; Rossi G. C.; Pasternak G. W.; Bodnar R. J. Antisense mapping of the MOR-1 opioid receptor clone: modulation of hyperphagia induced by DAMGO. J. Pharmacol. Exp. Ther. 282:1402-1407; 1997.
125. Li C. H.; Chung D. Isolation and structure of an untriakontapeptide with opiate activity from camel pituitary glands. Proc. Natl. Acad. Sci. USA 73:1145-1148; 1976.
126. Li S.; Zhu J.; Chen C.; Chen Y.-W.; Deriel J. K.; Ashby B.; Liu-Chen L.-Y. Molecular cloning and expression of a rat κ opioid receptor. Biochem. J. 295:629-633; 1993.
127. Ling G. S.; MacLeod J. M.; Lee S.; Lockhart S. H.; Pasternak G. W. Separation of morphine analgesia from physical dependence. Science 226:462-464; 1984.
128. Ling G. S. F.; Spiegel K.; Lockhart S. H.; Pasternak G. W. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J. Pharmacol. Exp. Ther. 232:149-155; 1985.
129. Lord J. A. H.; Waterfield A. A.; Hughes J.; Kosterlitz H. W. Endogenous opioid peptides: multiple agonists and receptors. Nature 267:495-499; 1977.
130. 1 in neuroblastoma x glioma NG108-15 hybrid cells. FEBS Lett. 403:91-94; 1997.
131. 2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 11:277-280; 1990.
132. 2-like mammalian octapeptide: possible role in opiate dependence and abstinence. Peptides 11:969-972; 1990.
133. Malin D. R.; Zadina J. E.; Lake J. R.; Rogillio R. B.; Leyva J. E.; Benson T. M.; Corriere L. S.; Handunge B. P.; Kastin A. J. Tyr-MIF-1 precipitates abstinence syndrome in morphine-dependent rats. Brain Res. 610:169-171; 1993.
134. Mansour A.; Fox C. A.; Akil H.; Watson S. J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18:22-29; 1995.
135. Mansour A.; Fox C. A.; Burke S.; Meng F.; Thompson R. C.; Akil H.; Watson S. J. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J. Comp. Anat. 350:412-438; 1994.
136. Mansour A.; Fox C. A.; Thompson R. C.; Akil H.; Watson S. J. μ-opioid receptor mRNA expression in the rat CNS: comparison to μ-opioid binding. Brain Res. 643:245-265; 1994.
137. Martin W. R.; Eades C. G.; Thompson A. J.; Huppler R. E.; Gilbert P. E. The effects of morphine- and nalorphine-like drugs in nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:517-532; 1976.
138. i2. Biochem. J. 267: 391-398; 1990.
139. Meng F.; Taylor L. P.; Hoversten M. T.; Ueda Y.; Ardati A.; Reinscheid R. K.; Monsma F. J.; Watson S. J.; Civelli O.; Akil H. Moving from the orphanin FQ receptor to an opioid receptor using four point mutations. J. Biol. Chem. 271: 32016-32020; 1996.
140. Meng F.; Xie G.-X.; Thompson R. C.; Mansour A.; Goldstein A.; Watson S. J.; Akil H. Cloning and pharmacological characterization of a rat κ opioid receptor. Proc. Natl. Acad. Sci. USA 90:9954-9958; 1993.
141. Meunier J. C.; Mollereau C.; Toll L.; Suaudeau C.; Molsand C.; Alvinerie P.; Butour J. L.; Guillemot J.-C.; Ferrara P.; Monsarrat B, Mazarquil H.; Vassart G.; Parmentier M.; Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377:532-535; 1995.
142. i) purified from bovine brain is a high affinity GTPase. J. Biol. Chem. 260:2057-2063; 1985.
143. Min B. H.; Augustin L. B.; Felsheim R. F.; Fuchs J. A.; Loh H. H. Genomic structure and analysis of promoter sequence of a mouse μ opioid receptor gene. Proc. Natl. Acad. Sci. USA 91:9081-9085; 1994.
144. Minami M.; Toya T.; Katao Y.; Maekawa K.; Nakamura S.; Onogi T.; Kaneko S.; Satoh M. Cloning and expression of a cDNA for the rat κ-opioid receptor. FEBS Lett. 329:291-295; 1993.
145. Miyamoto Y.; Bowen W. D.; Portoghese P. S.; Takemori A. E. Lack of involvement of delta-1 opioid receptors in the development of physical dependence on morphine in mice. J. Pharmacol. Exp. Ther. 270:37-39; 1994.
146. 2 opioid receptors in the development of morphine dependence in mice. J. Pharmacol. Exp. Ther. 264:1141-1145; 1993.
147. Mogil J. S.; Grisel J. E.; Reinscheid R. K.; Civelli O.; Grandy D. K. Orphanin FQ is a functional anti-opioid peptide. Neuroscience 75:333-337; 1996.
148. Mogil J. S.; Grisel J. E.; Zhang G.; Belknap J. K.; Grandy D. K. Functional antagonism of μ-, δ-, and κ-opioid antinociception by orphaninFQ. Neurosci. Lett. 214:131-134; 1996.
149. Mollereau C.; Parmentier M.; Mailleux P.; Butour J.-L.; Moisand C.; Chalon P.; Caput D.; Vassart G.; Meunier J.-C. ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization. FEBS Lett. 341: 33-38; 1994.
150. Mollereau C.; Simons M.-J.; Soularue P.; Liners F.; Vassart G.; Meunier J.-C.; Parmentier M. Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc. Natl. Acad. Sci. USA 93:8666-8670; 1996.
151. Murphy N. P.; Ly H. T.; Maidment N. T. Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience 75:1-4; 1996.
152. Musacchio J. M.; Greenspan D. L. The adenylate cyclase rebound response to naloxone in the NG108-15 cells. Effects of etorphine and other opiates. Neuropharmacology 25:833-837; 1986.
153. Nakanishi S.; Inoue A.; Kita T.; Nakamura M.; Chang A. C. Y.; Cohen S. N.; Numa S. Nucleotide sequence of cloned cDNA for bovine corticotropin-β-lipotropin precursor. Nature 278:423-427; 1979.
154. Neer E. J. Heterotrimeric G proteins: organizers of transmembrane signals. Cell 80:249-257; 1995.
155. Nestler, E. J.; Duman, R. S. G proteins and cyclic nucleotides in the nervous system. In: Siegel G. J.; Agranoff B. W.; Albers R. W.; Molinoff P. B.; eds. Basic Neurochemistry. New York: Raven Press, 1994; 429-448.
156. Nestler E. J.; Hope B. T.; Widnell K. L. Drug addiction: a model for the molecular basis of neural plasticity. Neuron 11:995-1006; 1993.
157. Nishi M.; Takeshima H.; Fukada K.; Kato S.; Mori K. cDNA cloning and pharmacological characterization of an opioid receptor with high affinities for κ-sub type-selective ligands. FEBS Lett. 330:77-80; 1993.
158. Nishino K.; Su Y. F.; Wong C.-S.; Watkins W. D.; Chang K.-J. Dissociation of mu opioid tolerance from receptor down-regulation in rat spinal cord. J. Pharmacol. Exp. Ther. 253:67-72; 1990.
159. Noble F.; Cox B. M. Differential desensitization of μ- and δ-opioid receptors in selected neural pathways following chronic morphine treatment. Br. J. Pharmacol. 117:161-169; 1996.
160. Noda M.; Furutani Y.; Takehashi H.; Toyosato M.; Hirose T.; Inayama S.; Nakanishi S.; Numa S. Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature 295:202-206; 1982.
161. Northup J. K.; Sternweis P. C.; Smigel M. D.; Schleifer L. S.; Ross E. M.; Gilman A. G. Purification of the regulatory component of adenylate cyclase. Proc. Natl. Acad. Sci. USA 77:6516-6520; 1980.
162. Nothacker H.-P.; Reinscheid R. K.; Mansour A.; Henningsen R. A.; Ardati A.; Monsma F. J.; Watson S. J.; Civelli O. Primary structure and tissue distribution of the orphanin FQ precursor. Proc. Natl. Acad. Sci. USA 93:8677-8682; 1996.
163. Numa S.; Nakanishi S. Corticotropin-β-lipotropin precursor - a multi-hormone precursor - and its gene. Trends Biochem. Sci. 274-277; 1981.
164. Pak Y.; O'Dowd B. F.; George S. R. Agonist-induced desensitization of the μ opioid receptor is determined by threonine 394 preceded by acidic amino acids in the COOH-terminal tail. J. Biol. Chem. 272:24961-24965; 1997.
165. Pasternak G. W.; Childers S. R.; Snyder S. H. Naloxozone, a long-acting opiate antagonist: effects on intact animals and on opiate receptor binding in vitro. J. Pharmacol. Exp. Ther. 214:455-462; 1980.
166. Pasternak G. W.; Goodman R.; Snyder S. H. An endogenous morphine-like factor in mammalian brain. Life Sci. 16:1765-1769; 1975.
167. Pasternak G. W.; Wood P. J. Minireview. Multiple mu opiate receptors. Life Sci. 38:1889-1898; 1986.
168. Payza K.; Akar C. A.; Yang H.-Y. T. Neuropeptide FF receptors: structure-activity relationship and effect of morphine. J. Pharmacol. Exp. Ther. 267:88-94; 1993.
169. Pei G.; Kieffer B. L.; Lefkowitz R. J.; Freedman N. J. Agonist-dependent phosphorylation of the mouse δ-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C. Mol. Pharmacol. 48:173-177; 1995.
170. Perry S. J.; Huang E. Y.-K.; Cronk D.; Bagust J.; Sharma R.; Walker R. J.; Wilson S.; Burke J. F. A human gene encoding morphine modulating peptides related to NPFF and FMRF-amide. FEBS Lett. 409:426-430; 1997.
171. Pert C. B.; Pasternak G.; Snyder S. H. Opiate agonists and antagonists discriminate by receptor binding in rat brain. Science 182:1359-1361; 1973.
172. Pert C. B.; Snyder S. H. Opiate receptor: demonstration in nervous tissue. Science 179:1011-1014; 1973.
173. Pert C. B.; Snyder S. H. Properties of opiate-receptor binding in rat
174. Pfeiffer A.; Pasi A.; Mehraein P.; Herz A. A subclassification of κ-sites in human brain by use of dynorphin 1-17. Neuropeptides 2:89-97; 1981.
175. Pfeuffer T.; Helmreich E. J. M. Activation of pigeon erythrocyte membrane adenylate cyclase by guanyl nucleotide analogues and separation of a nucleotide binding protein. J. Biol. Chem. 250:867-876; 1975.
176. 3H]-SKF 10047 binding to rat brain membranes: evidence for kappa isoreceptors. Life Sci. 33: 263-265; 1983.
177. Puttfarcken P. S.; Werling L. L.; Cox B. M. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at μ opioid receptors. Mol. Pharmacol. 33:520-527; 1988.
178. 2b receptors. Peptides 15:401-404; 1994.
179. Raynor K.; Kong H.; Hines J.; Kong G.; Benovic J.; Yasuda K.; Bell G. I.; Reisine T. Molecular mechanisms of agonist-induced desensitization of the cloned mouse kappa opioid receptor. J. Pharmacol. Exp. Ther. 270:1381-1386; 1994.
180. Reinscheid R. K.; Nothacker H.-P.; Bourson A.; Ardati A.; Henningsen R. A.; Bunzow J. R.; Grandy D. K.; Langen H.; Monsama F. J., Jr.; Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270:792-794; 1995.
181. Reisine T.; Bell G. I. Molecular biology of opioid receptors. Trends Neurosci. 16:506-510; 1993.
182. Rodbell M.; Krans H. M. J.; Pohl S. L.; Birnbaumer L. The glucagon-sensitive adenylyl cyclase system in plasma membranes of rat liver. IV. Binding of glucagon: effect of guanyl nucleotides. J. Biol. Chem. 246:1872-1876; 1971.
183. Roerig S. C.; Loh H. H.; Law P. Y. Identification of three separate guanine nucleotide-binding proteins that interact with the δ-opioid receptor in NG108-15 neuroblastoma x glioma hybrid cells. Mol. Pharmacol. 41:822-831; 1992.
184. Ronnekleiv O. K.; Bosch M. A.; Cunningham M. J.; Wagner E. J.; Grandy D. K.; Kelly M. J. Downregulation of μ-opioid receptor mRNA in the mediobasal hypothalamus of the female guinea pig following morphine treatment. Neurosci. Lett. 216:129-132; 1996.
185. Ross E. M.; Oilman A. G. Reconstitution of catecholamine-sensitive adenylate cyclase activity: interaction of solubilized components with receptor-replete membranes. Proc. Natl. Acad. Sci. USA 74:3715-3719; 1977.
186. Ross E. M.; Oilman A. G. Resolution of some components of adenylate cyclase necessary for catalytic activity. J. Biol. Chem. 252:6966-6969; 1977.
187. Rossi G. C.; Leventhal L.; Pan Y. X.; Cole J.; Su W.; Bodnar R. J.; Pasternak G. W. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6β-glucuronide antinociception. J. Pharmacol. Exp. Ther. 281:109-114; 1997.
188. Rossi G. C.; Leventhal L.; Pasternak G. Naloxone sensitive orphanin FQ-induced analgesia in mice. Eur. J. Pharmacol. 311:R7-R8; 1996.
189. ncx opioid binding sites in vitro and in vivo. Peptides 13:691-694; 1992.
190. 5]enkephalin: further evidence for two μ-binding sites. Eur. J. Pharmacol. 160:71-82; 1989.
191. Rothman R. B.; Danks J. A.; Jacobson A. E.; Burke T. R.; Rice K. C.; Tortella F. C.; Holaday J. W. Morphine tolerance increases μ-noncompetitive δ binding sites. Eur. J. Pharmacol. 124:113-119; 1986.
192. Schofield P. R.; McFarland K. C.; Hayflick J. S.; Wilcox J. N.; Cho T. M.; Roy S.; Lee N. M.; Loh H. H.; Seeburg P. H. Molecular characterization of a new immunoglobulin superfamily protein with potential roles in opioid binding and cell contact. EMBO J. 8:489-495; 1989.
193. Selley D. E.; Nestler E. J.; Breivogel C. S.; Childers S. R. Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decreases in activity after chronic morphine treatment. Brain Res. 746:10-18; 1997.
194. Sharma S. K.; Klee W. A.; Nirenberg M. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc. Natl. Acad. Sci. USA 72:3092-3096; 1975.
195. Sharma S. K.; Klee W. A.; Nirenberg M. Opiate-dependent modulation of adenylate cyclase. Proc. Natl. Acad. Sci. USA 74:3365-3369; 1977.
196. Sharma S. K.; Nirenberg M.; Klee W. A. Morphine receptors as regulators of adenylate cyclase activity. Proc. Natl. Acad. Sci. USA 72:590-594; 1975.
197. Shen K.-F.; Crain S. M. Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence. Brain Res. 636:286-297; 1994.
198. Shen K.-F.; Crain S. M. Specific N- or C-terminus modified dynorphin and β-endorphin peptides can selectively block excitatory opioid receptor functions in sensory neurons and unmask potent inhibitory effects of opioid agonists. Brain Res. 673:30-38; 1995.
199. Shen K.-F.; Crain S. M. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res. 757:176-190; 1997.
200. 35S]GTPyS autoradiography in rat brain. J. Neurosci. 16:2684-2692; 1996.
201. Sim L. J.; Selley D. E.; Xiao R.; Childers S. R. Differences in G-protein activation by μ and δ-opioid and cannabinoid, receptors in rat striatum. Eur. J. Pharmacol. 307:97-105; 1996.
202. 3H]etorphine. Proc. Natl. Acad. Sci. USA 70:1947-1949; 1973.
203. Simonin F.; Gaveriaux-Ruff C.; Befort K.; Matthes H.; Lannes B.; Micheletti G.; Mattei M.-G.; Charron G.; Bloch B.; Kieffer B. κ-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc. Natl. Acad. Sci. USA 92:7006-7010; 1995.
204. Smith, A. P.; Law, P.-Y. Role of opioid receptors in narcotic dependence/tolerance. In: Pasternak G.; ed. The Opiate Receptors. Clifton, NJ: Humana Press, 1988; 441-485.
205. Smith J. R.; Simon E. J. Selective protection of stereospecific enkephalin and opiate binding against inactivation by N-ethylmaleimide: evidence for two classes of opiate receptors. Proc. Natl. Acad. Sci. USA 77:2841-2844; 1980.
206. Sofuoglu M.; Portoghese P. S.; Takemori A. E. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J. Pharmacol. Exp. Ther. 257:676-680; 1991.
207. Stern A. S.; Jones B. N.; Shively J. E.; Stein S.; Udenfriend S. Two adrenal opioid polypeptides: proposed intermediates in the processing of proenkephalin. Proc. Natl. Acad. Sci. USA 78:1962-1966; 1981.
208. 7] from bovine adrenal medullary granules and striatum. Proc. Natl. Acad. Sci. USA 76:6680-6683; 1979.
209. Tao P.-L.; Law P.-Y.; Loh H. H. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment. J. Pharmacol. Exp. Ther. 240:809-816; 1987.
210. Tao P.-L.; Lee H.-Y.; Chang L.-R.; Loh H. H. Decrease in μ-opioid receptor binding capacity in rat brain after chronic PL017 treatment. Brain Res. 526:270-275; 1990.
211. 5]enkephalin on rat brain opioid receptors. Eur. J. Pharmacol. 201:209-214; 1991.
212. Tempel A.; Gardner E. L.; Zukin R. S. Visualization of opiate receptor upregulation by light microscopy autoradiography. Proc. Natl. Acad. Sci. USA 81:3893-3897; 1984.
213. Terenius L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacol. Toxicol. 32:317-320; 1973.
214. Terenius L.; Wahlstrom A. Search for an endogenous ligand for the opiate receptor. Acta Physiol. Scand. 94:74-81; 1975.
215. Teschemacher H.; Opheim K. E.; Cox B. M.; Goldstein A. A peptide-like substance from pituitary that acts like morphine. 1. Isolation. Life Sci. 16:1771-1776; 1975.
216. Thompson R. C.; Mansour A.; Akil H.; Watson S. J. Cloning and pharmacological characterization of a rat μ opioid receptor. Neuron 11:903-913; 1993.
217. Tian J.-H.; Xu W.; Fang Y.; Mogil J. S.; Grisel J. E.; Grandy D. K.; Han J.-S. Bidirectional modulatory effect of orphanin FQ in morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br. J. Pharmacol. 120:676-680; 1997.
218. Trapaidze N.; Keith D. E.; Cvejic S.; Evans C. J.; Devi L. A. Sequestration of the δ-opioid receptor. J. Biol. Chem. 271: 29279-29285; 1996.
219. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47:848-854; 1995.
220. Unterwald E. M.; Rubenfeld J. M.; Imai Y.; Wang J.-B.; Uhl G. R.; Kreek M. J. Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol. Brain Res. 33:351-355; 1995.
221. 4]deltorphin with δ-opioid receptor subtypes in vivo. Eur. J. Pharmacol. 252:133-137; 1994.
222. Wang J.-B.; Johnson P. S.; Persico A. M.; Hawkins A. L.; Griffin C. A.; Uhl G. R. Human μ opiate receptor: cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett. 338:217-222; 1994.
223. Wang J. B.; Imai Y.; Eppler C. M.; Gregor P.; Spivak C. E.; Uhl G. μ opiate receptor: cDNA cloning and expression. Proc. Natl. Acad. Sci USA 90:10230-10234; 1993.
224. Wang L.; Gintzler A. R. Morphine tolerance and physical dependence: reversal of opioid inhibition to enhancement of cyclic AMP formation. J. Neurochem. 64:1102-1106; 1995.
225. Wang L.; Gintzler A. R. Altered μ-opiate receptor-G protein signal transduction following chronic morphine exposure. J. Neurochem. 68:248-254; 1997.
226. Wang Z.; Bilsky E. J.; Porreca F.; Sadee W. Constitutive μ receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci. 54:339-350; 1994.
227. Werling L.; McMahon P. N.; Cox B. M. Selective changes in μ opioid receptor properties induced by chronic morphine exposure. Proc. Natl. Acad. Sci. USA 86:6393-6397; 1989.
228. Wheeler G. L.; Bitensky M. W. A light-activated GTPase in vertebrate photoreceptors: regulation of light-activated cGMP by phosphodiesterase. Proc. Natl. Acad. Sci. USA 74:4238-4242; 1977.
229. Wolozin B. L.; Pasternak G. W. Classification of multiple morphine and enkephalin binding sites in the central nervous system. Proc. Natl. Acad. Sci. USA 78:6181-6185; 1981.
230. Wood, P. W.; Iyengar, S.; Pasternak G. W. Central actions of opiates and opioid peptides. In: Pasternak, G.W.; ed. The Opiate Receptors. Clifton, NJ: Humana Press, 1988; 307-356.
231. Wu G.; Lu Z.-H.; Ledeen R. W. Interaction of the δ-opioid receptor with GM1 ganglioside: conversion from inhibitory to excitatory mode. Mol. Brain Res. 44:341-346; 1997.
232. Xie G.-X.; Miyajima A.; Goldstein A. Expression cloning of cDNA encoding a seven-helix receptor from human placenta with affinity for opioid ligands. Proc. Natl. Acad. Sci. USA 89:4124-4128; 1992.
233. ncx sites in rat brain: further evidence for heterogeneity. Peptides 13:1207-1213; 1992.
234. 1 receptor agonist, in the rat formalin test. Neuroscience 81:249-254; 1997.
235. Yang H.-Y. T.; Fratta W.; Majane E. A.; Costa E. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc. Natl. Acad. Sci. USA 82:7757-7761; 1985.
236. Yasuda K.; Raynor K.; Kong H.; Breder C. D.; Takeda J.; Reisine T.; Bell G. I. Cloning and functional comparison of κ and δ opioid receptors from mouse brain. Proc. Natl. Acad. Sci. USA 90:6736-6740; 1993.
237. Yoburn B. C.; Billings B.; Duttaroy A. Opioid receptor regulation in mice. J. Pharmacol. Exp. Ther. 265:314-320; 1993.
238. Yu V. C.; Eiger S.; Duan D.-S.; Lameh J.; Sadee W. Regulation of cyclic AMP by the μ-opioid receptor in human neuroblastoma SH-SY5Y cells. J. Neurochem. 55:1390-1396; 1990.
239. Yu V. C.; Sadee W. Efficacy and tolerance of narcotic analgesics at the mu opioid receptor in differentiated human neuroblastoma cells. J. Pharmacol. Exp. Ther. 245:350-355; 1988.
240. Zadina J. E.; Chang S.-L.; Ge L.-J.; Kastin A. J. Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells. J. Pharmacol. Exp. Ther. 265:254-262; 1993.
241. Zadina J. E.; Hackler L.; Ge L.-J.; Kastin A. J. A potent and selective endogenous agonist for the μ-opiate receptor. Nature 386:499-502; 1997.
242. Zadina J. E.; Harrison L. M.; Ge L.-J.; Kastin A. J.; Chang S. L. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells. J. Pharmacol. Exp. Ther. 270:1086-1096; 1994.
243. Zadina J. E.; Kastin A. J. Interactions between the antiopiate Tyr-MIF-1 and the mu opiate morphiceptin at their respective binding sites in brain. Peptides 6:965-970; 1985.
244. Zadina J. E.; Kastin A. J.; Ge L.-J.; Chang S. L. Novel peptides and mechanisms of opiate tolerance. Reg. Peptides (Suppl 1):S195-S196; 1994.
245. Zadina J. E.; Kastin A. J.; Ge L.-J.; Gulden H.; Bungart K. Chronic, but not acute, administration of morphine alters antiopiate (Tyr-MIF-1) binding sites in rat brain. Life Sci. 44:555-561; 1989.
246. Zadina J. E.; Kastin A. J.; Ge L.-J.; Hackler L. Mu, delta, and kappa opiate receptor binding of Tyr-MIF-1 and of Tyr-W-MIF-1, its active fragments, and two potent analogs. Life Sci. 55:PL461-PL466; 1994.
247. Zadina J. E.; Kastin A. J.; Harrison L. M.; Ge L.-J.; Chang S. L. Opiate receptor changes after chronic exposure to agonists and antagonists. Ann. NY Acad. Sci. 757:353-361; 1995.
248. 2). Neurosci. Lett. 155:220-222; 1993.
249. Zadina J. E.; Kastin A. J.; Kersh D.; Wyatt A. Tyr-MIF-1 and hemorphin can act as opiate agonists as well as antagonists in the guinea pig ileum. Life Sci. 51:869-885; 1992.
250. 2) in rat brain. Pharmacol. Biochem. Behav. 17: 1193-1198; 1982.
251. Zhang L.; Yu Y.; Mackin S.; Weight F. F.; Uhl G. R.; Wang J. B. Differential μ opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. J. Biol. Chem. 271:11449-11454; 1996.
252. Zimprich A.; Simon T.; Hollt V. Cloning and expression of an isoform of the rat μ opioid receptor (rMOR1B) which differs in agonist induced desensitization for rMOR1. FEBS Lett. 359:142-146; 1995.
253. 2 opioid receptors. Proc. Natl. Acad. Sci. USA 85:4061-4065; 1988.